Notice2026-19431
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 23, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 183 (Wednesday, September 23, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 183 (Wednesday, September 23, 2026)]
[Notices]
[Pages 60382-60383]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-19431]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing to achieve expeditious
commercialization of results of federally-funded research for the
benefit of the public health.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development, 31
Center Drive, Room 4A25, MSC2479, Bethesda, MD 20892-2479;
<a href="/cdn-cgi/l/email-protection#296761656b60767d4c4a417d5b48475a4f4c5b694448404507474041074e465f"><span class="__cf_email__" data-cfemail="5a1412161813050e3f39320e283b34293c3f281a373b333674343332743d352c">[email protected]</span></a>. A signed Confidential Disclosure
Agreement may be required to receive any unpublished information.
SUPPLEMENTARY INFORMATION: Technology description follows.
Hematopoietic Stem Cell and Progenitor Cell Transplantation Therapy
Technology
Available for licensing and commercial development are patent
rights covering recombinant bivalent (bi) single-chain variable
fragment (scFV) minibody targeting the cMPL receptor on HSPCs, fused
with diphtheria toxin (DT) truncated at residue 390 (DT390-
biscFV(cMPL)) that can be used to deplete HSPCs with increased safety
in patients undergoing HSPC transplantation. Patient conditioning is a
critical initial step in hematopoietic stem and progenitor cell (HSPC)
transplantation procedures, especially for leukemia patients, that
enables marrow engraftment of infused cells. Conditioning regimens have
traditionally been achieved by delivering cytotoxic doses of
chemotherapeutic agents and radiation. However, these regimens are
associated with significant morbidity and mortality and cannot be used
safely in elderly or subjects with comorbidities.
Potential Commercial Applications:
<bullet> Use as a novel conditioning regimen with increased safety
for patients undergoing transplantation.
<bullet> Investigational tool to study hematopoietic stem and
progenitor cell (HSPC) biology and improve gene therapy and cell
therapy.
Competitive Advantages:
[[Page 60383]]
<bullet> transplantation efficacy.
<bullet> Limits chemotherapeutic cytotoxicity.
<bullet> Better penetrants into deep tissue, such as bone marrow
niche.
<bullet> Short half-life allowing rapid clearance before cell re-
infusion.
<bullet> More efficiently dimerizes cMPL receptor than the whole
IgG.
Development Stage:
<bullet> Preclinical.
<bullet> In vivo data available (animal).
Related Publications:
<bullet> Araki D, Hong SG, Linde N, Fisk B, Redekar N, Salisbury-
Ruf C, Krouse A, Engels T, Golomb J, Dagur P, Panicker SR, Kanthi Y,
Magnani DM, Wang Z, Larochelle A. cMPL-based purification and depletion
of human hematopoietic stem cells: implications for pretransplant
conditioning. Blood. 2025 Jun 19;145(25):2978-2991. doi: 10.1182/
blood.2024024636. PMID: 40009502; PMCID: PMC12226764.
Intellectual Property: HHS Ref. No.: E-188-2021-0.
<bullet> U.S. Provisional Application No. 63/251,883 filed October
4, 2022.
<bullet> PCT Application No. PCT/US22/77326 filed September 30,
2022.
<bullet> U.S. Application No. 18/688,899 filed March 4, 2024.
<bullet> European Patent Application No. 22813001.9 filed March 8,
2024.
<bullet> Israel Patent Application No. 311590 filed March 19, 2024.
<bullet> China Patent Application No. 202280065162.6 filed March
26, 2024.
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize this technology. For collaboration
opportunities, please contact Dr. Vincent Kolesnitchenko, 301-594-4115
or <a href="/cdn-cgi/l/email-protection#a6d0cd93d7e6c8cfce88c1c9d0"><span class="__cf_email__" data-cfemail="4a3c217f3b0a242322642d253c">[email protected]</span></a> and reference E-188-2021-0.
Licensing Contact: Vincent Kolesnitchenko, Ph.D.; 301-594-4115;
<a href="/cdn-cgi/l/email-protection#6a1c015f1b2a040302440d051c"><span class="__cf_email__" data-cfemail="9debf6a8ecddf3f4f5b3faf2eb">[email protected]</span></a>.
``This Notice is in accordance with 37 CFR 404.4 Authority to grant
licenses.''
Dated: September 21, 2026.
Vincent A. Kolesnitchenko,
Senior Technology Transfer Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2026-19431 Filed 9-22-26; 8:45 am]
BILLING CODE 4167-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 23, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.